

Market Scope[®]

2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases

Global Analysis for 2023 to 2029

\$1.3B

2024 MARKET
FORECAST

222

COMPREHENSIVE
PAGES

19

COMPETITOR
PROFILES

8

GEOGRAPHIC AND
ECONOMIC BREAKOUTS

What's New

AUTHOR
Peter Downs

PUBLISHED
October 2024

This first-edition “2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases” estimates the prevalence of nonexudative retinal diseases and forecasts the treatment market by region for complement inhibitors, gene therapies, and more.

The report examines clinical-stage drug-development programs, reviews the development stages of drug-delivery platforms, and analyzes trends in doctor interest in complement inhibitors in both the United States and Western Europe, as well as patient dosing with complement inhibitors in the United States.


Market Scope

2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases


The “2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases” analyzes the market for anti-VEGFs and other drugs for the treatment of exudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines the market’s evolution, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 40 competitors are profiled, with discussion of their products, strategic market position, background, and outlook. Our coverage includes:

- Discussions of nonexudative retinal diseases and their risk factors.
- Diagnosis and treatment of these diseases.
- A global view of retinal care and retina specialists.
- Pharmaceuticals and biologics in the marketplace for nonexudative retinal disease.
- Investigational agents in the development pipeline.
- Profiles of companies developing and marketing nonexudative retinal disease pharmaceuticals, plus a listing of additional companies with preclinical programs

Nonexudative Retinal Disease Pharmaceuticals Revenue Share by Product Type



Global Nonexudative Retinal Disease Pharmaceutical Market by Company Share of Revenue



Market Scope designed this report to provide value to members of the ophthalmic industry who participate in the retinal pharmaceuticals market (or are weighing the option of doing so), market analysts, retina specialists, investors, and any other parties interested in the marketplace for these retinal treatments.

How to Order

Order your “2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases” now at www.market-scope.com or contact us directly via email or phone.



ENTERPRISE LICENSE

2024 Retinal Pharmaceuticals
Market Report: GA and Other
Nonexudative Diseases

\$8,200

(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)



SINGLE-USER LICENSE

2024 Retinal Pharmaceuticals
Market Report: GA and Other
Nonexudative Diseases

\$5,500



Printed Copy

\$250



ONE-YEAR SUBSCRIPTION

Ophthalmic Market
Perspectives Newsletter

\$1,700



Monthly Paper Copies

\$100

314.835.0600 | info@market-scope.com

Our Process

Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

